Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Key Points Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The ...

Eli Lilly and Novo Nordisk are currently the only drugmakers with FDA approved weight-loss medicines on the U.S. market.

Kiran Musunuru, a University of Pennsylvania cardiologist and leading gene-editing researcher, thinks it’s possible. Musunuru ...

Eli Lilly is tagging along on actress Kym Whitley’s blockbuster summer in a fresh Zepbound partnership with the “Happy ...

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for ...

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the ...

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

The first oral pill for obstructive sleep apnea could be around the corner after company Apnimed reported positive results ...